Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 4 - The Untold Story

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK plc (NYSE:GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ:ANAB) in the Delaware Chancery Court.

Benzinga

Could AI help defeat antibiotic-resistant superbugs? UK scientists are trying to find out

The three-year project aims to use AI to develop new tools in the fight against pathogens that can evade existing treatments.

Euronews

Troubled drinks giant Diageo names former Tesco boss to lead turnaround push

Appointment of Sir Dave Lewis as CEO represents significant coup for struggling FTSE 100 firm

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks mixed and pound dips amid Budget tax hints

The FTSE 100 Index closed up 13.59 points at 9,714.96.

Evening Standard

We need clarity on big pharma’s tax breaks

Letters: Pharmaceutical giants like GSK should be more transparent about the generous tax breaks they get from the UK government, says Mike Lewis

The Guardian - UK

UK must reform drug pricing to become life sciences superpower, says GSK boss

Shares jump on higher profits as Emma Walmsley is ‘hopeful’ standoff with NHS can be resolved

The Guardian - UK

GSK boosted by cancer and HIV drugs as Emma Walmsley bows out

Shares in the company rose on Wednesday morning as a result, lifting to their highest level for more than a year.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.

Benzinga

FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep

On Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.

Benzinga

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD-GRN).

Benzinga

UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment

The U.K.’s National Institute for Health and Care Excellence (NICE) is recommending a treatment from a firm jointly owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE) and Shionogi Inc.

Benzinga

GSK chief doesn't buy that the CEO role has become unsustainable

The co-CEO model may work with the right “cocktail” combination, but CEOs must be prepared to give the position “everything you possibly have,” she said.

Fortune

Are trees getting taller? Plus teenage smoking and why females live longer

These are the most groundbreaking stories from the new frontier of science and technology right now

Evening Standard

FTSE 100 hits another high despite concerns over US government shutdown

Drug companies AstraZeneca, Hikma Pharmaceuticals and GSK were all big risers.

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.

The Guardian - UK

Emma Walmsley steadied GSK – but doubts linger over growth targets

The outgoing chief executive reshaped the drugmaker, yet scepticism persists over promised revenues

Benzinga

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

CEO of drugmaker GSK to step down by year's end

GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down Dec. 31 after more than eight years at the head of the London-based drugmaker

The Independent UK

Emma Walmsley steps down as CEO of GSK as pharmaceutical industry faces upheaval

The drug and vaccine maker is a £60bn firm – one of the biggest in the UK

International Business Times

GSK Switches CEO As Trump Tariffs Test Pharma

British pharmaceutical giant GSK on Monday said longtime chief executive Emma Walmsley will be replaced by its chief commercial officer in January, as the company navigates US tariffs on the sector.

Evening Standard

GSK’s boss Emma Walmsley to step down after eight-year tenure

Dame Emma was the first woman to run a major pharmaceutical company when she became chief executive in 2017.

The Guardian - UK

GSK’s Emma Walmsley to step down as chief executive after eight years

Chief commercial officer Luke Miels to take over as CEO at Britain’s second-biggest drugmaker

Evening Standard

FTSE 100 Live 29 September: Index nears record, GSK shares rise on CEO change

GSK chief executive Emma Walmsley is to step down after more than eight years running the pharmaceuticals giant.

Evening Standard

Brighter US outlook fires up European stocks

The FTSE 100 index closed up 70.85 points, or 0.8%, at 9,284.83.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.